Hikma Bolsters Injectables With Completion Of Xellia Deal
CEO Says Addition Of Finished-Dose Assets Will Enhance Portfolio And Technology
As it completed its takeover of Xellia’s finished dosage form business and related assets, Hikma set out how it expects its injectables business to benefit from the acquisition.
